TAG:
cap
Consolidation: Threat Or Opportunity
By R. Lewis Dark | From the Volume V No. 13 – September 28, 1998 Issue
IS CONSOLIDATION GOOD OR BAD FOR OUR HEALTHCARE SYSTEM? I don’t know if any of us could accurately answer that question. For better or for worse, big corporations will continue to buy up the little guys. I do feel confident in predicting that ongoing consolidation will occur in all areas of health…
Bayer Acquires Chiron In Consolidation Move
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: As expected, consolidation within the diagnostics industry continues. This time it is Bayer, spending $1.1 billion to acquire Chiron’s diagnostics business. Once completed, Bayer will be the fourth-largest diagnostics company in the world. Laboratory customers of both firms…
Chiron Is Biotech Firm, Respected For Innovation
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: Chiron is respected for its leadership in branched DNA and viral load technologies. The company had high expectations for its diagnostics group, particularly after its purchase of Ciba Corning. But rapid consolidation of the diagnostics industry changed Chiron’s opportunity…
AutoCyte Moves One Step Closer To FDA Approval
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs…
Unilab’s Bid To Buy Meris Will Shake Up California
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: More laboratory overcapacity may be removed from the California marketplace if Unilab purchases Meris Laboratories. Unilab’s offer to buy Meris must be cleared by the bankruptcy court and other bidders may surface during the coming weeks. These events are a reminder that fi…
Pharmacogenomics Is The Coming Wave
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: It may be gloom and doom today in the clinical laboratory industry, but long term prospects for diagnostic testing are brightening. Increased understanding of human genetics drives new discoveries about how and why the same drug affects individuals differently. Biotech compan…
Genetic Testing Almost Accented In Market Place
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: Advances in molecular and genetic science have generated the first generation of diagnostic assays for clinical use. As these assays reach the public, acceptance is not immediate. Obstacles are many: ethical, cultural, clinical, and economic. Oncormed’s experience during th…
DIANON Shoots At Urocor, Makes Unwelcome Offer
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: It pays to know your friends. Last month DIANON Systems announced an unsolicited offer to acquire UroCor. The offer, following months of ongoing discussions between the two companies, was clearly unwelcome at UroCor. Both companies are pushing hard to evolve disease managemen…
Veterans Administration Network Restructures Using Partnering, Telepathology
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: Economic pressures are forcing even the traditional and staid Veterans Administration to extensively reconfigure its laboratory services. At this year’s Executive War College in New Orleans, participants learned how one eight-hospi…
Problems In PPM lndustry Affect Pathology Practices
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
DURING 1998, THE FINANCIAL WOES of many physician practice management (PPM) companies caught healthcare experts, investors, and financial experts by surprise. Problems with the PPM industry could not come at a worse time for the pathology profession. At the very moment that several pathology-based P…
CURRENT ISSUE
Volume XXXIII, No. 4 – March 23, 2026
A federal court ruling has established a safe harbor for clinical labs when they run tests ordered by physicians. Lab leaders should examine this briefing for pitfalls. Also, it turns out that providers may be ordering inappropriate vitamin D tests, according to one expert.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized